Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

3M buying maker of people tracking devices

August 31, 2010 4:45 am | by The Associated Press | News | Comments

Manufacturing conglomerate 3M says it has agreed to pay $230 million in cash for an Israeli company that makes technology used to keep track of people.The company, Attenti Holdings SA, makes systems that can be used, for example, to track the movements of people awaiting trial or are on...

Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding

August 31, 2010 4:37 am | by EurekAlert | News | Comments

(JAMA and Archives Journals) Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a...

TOPICS:

Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference

August 31, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

WALTHAM, Mass., Aug. 31 /- Repligen Corporation (Nasdaq: RGEN ) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 13th, 2010 at 12:05 p.m. EDT...

TOPICS:
Advertisement

Actemra Post-Launch Success Continues to Gain Momentum with Broader Adoption Compared to Biologic Analog Launches and a Professional Marketing Campaign That Resonates with Rhe...

August 31, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

EXTON, Pa., Aug. 31 /- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA . Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an...

TOPICS:

Halozyme Provides HYLENEX® Product Reintroduction Update

August 31, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Aug. 31 /- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter...

TOPICS:

The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports

August 31, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT... -- DALLAS, Texas, August 31, 2010 /-

TOPICS:

Henry Schein Provides Health Care Products for Relief After Flooding in Pakistan

August 31, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

MELVILLE, N.Y., Aug. 31 /- Henry Schein, Inc. (Nasdaq: HSIC ), the largest provider of health care products and services to office-based practitioners, is working with its non-governmental organization (NGO) partners – Direct Relief, International Medical Corps, Americares, and...

TOPICS:

NIST-traceable Temperature Tracking Provides Visual Alert RadarFind Sensor Now Waterproof Certified

August 31, 2010 4:34 am | by Bio-Medicine.Org | News | Comments

MORRISVILLE, N.C., Aug. 31 /- TeleTracking Technologies' RadarFind real-time locating distributed sensor network now includes temperature measurement that is NIST traceable and meets College of American Pathologist requirements with new temperature sensors certified to be waterproof and...

TOPICS:
Advertisement

The neural basis of the depressive self

August 31, 2010 4:33 am | by EurekAlert | News | Comments

(European College of Neuropsychopharmacology) In the general population, depression is still frequently associated with bad lifestyle, impairment of volition and "psychological weakness." However, the results of brain imaging studies clearly have confirmed that depression is a true brain...

TOPICS:

Futures in Biotech 65: Tackling Genetic Disease

August 31, 2010 1:33 am | Podcasts | Comments

Hosts: Marc Pelletier and Dave Brodbeck Progress in molecular biology and the latest strategies for tackling genetic disease. Guest: David Thomas, professor and chair, Department of Biochemistry, McGill University; Canada Research Chair in Molecular Genetics We invite you to read, add to,...

M+W group pushing growth in photovoltaic power plants: establishment of M+W Solar

August 31, 2010 1:33 am | by I-Micronews | News | Comments

Exhibitor at the PVSEC trade fair in Valencia/Spain - M+W group awarded ?Solar Industry Award 2010?

OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces

August 31, 2010 1:32 am | by Bio-Medicine.Org | News | Comments

HOUSTON, Aug. 31 /- OrthoAccel Technologies, Inc. announced this week that following a successful limited market release of AcceleDent last October it will be initiating a full-market release throughout the United Kingdom this coming September.  Availability of AcceleDent , which is...

TOPICS:

Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products

August 31, 2010 1:32 am | by Bio-Medicine.Org | News | Comments

LONDON, Aug. 31 /- Following a recent analysis of the medical imaging devices market, Frost & Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with the "2010 South African Medical Imaging Product Quality Leadership Award".  Statscan, Lodox's digital x-ray product, stunned the...

TOPICS:

Combining resistance and endurance training best for heart health

August 30, 2010 10:33 pm | by EurekAlert | News | Comments

(Radiological Society of North America) A study of triathletes reveals that the heart adapts to triathlon training by working more efficiently.

TOPICS:

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

August 30, 2010 7:32 pm | by Bio-Medicine.Org | News | Comments

LONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /- GlaxoSmithKline (NYSE: GSK ) and Valeant Pharmaceuticals International (NYSE: VRX ) announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading